Ventyx Biosciences

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in Encinitas, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ventyx Biosciences reports Q1 losses, eyes market growth opportunities

Ventyx Biosciences navigates financial challenges with strong pipeline progress and strategic cash reserves.
Confidence in drug efficacy and proactive commercial planning position the company for market success.
Challenges from market competition and strategic decisions are balanced by growth opportunities and diversification.
Engagement with stakeholders and ongoing program advancements drive optimism for future growth and development.

Ventyx Biosciences progresses in Phase II trials amid commercial challenges

Ventyx Biosciences shows promising progress in Phase II trials for VTX958 and VTX002, with a focus on immune diseases like ulcerative colitis and psoriasis.
Challenges in commercial performance and trial diversity persist, but opportunities lie in upcoming Phase II results and potential expansion into new indications.
The company's financial performance reflects increased R&D investment, while strategic decisions on drug development and market positioning are crucial for future success.
Overall, Ventyx's innovative therapies and perseverance in trials position it for growth, pending successful Phase II outcomes and strategic adaptations.

Ventyx Biosciences reports promising Q1 results, eyes strategic partnerships

Ventyx Biosciences showcased strong performance in key inhibitors and IBD assets, despite facing financial challenges and the need to navigate regulatory complexities. The company's focus on innovation, upcoming trials, and potential partnerships positions them well for future growth and success in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going

Ventyx Biosciences, Inc. has three interesting molecules in inflammatory diseases. Each is in a different pathway validated by approved drugs.

Ventyx: Focusing On Competitive Differences Will Help

New directors replace current directors Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar Choksey New directors replace current directors Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar Choksey

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D.

ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it will host an R&D event on Thursday, January 26, 2023 in New York City from 9-11:30 a.m. ET. The event will highlight key aspects of Ventyx's clinical-stage and discovery programs.

Ventyx Biosciences to Host R&D Event on January 26, 2023

The mean of analysts' price targets for Ventyx Biosciences, Inc. (VTYX) points to a 70.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 71% Upside in Ventyx Biosciences, Inc. (VTYX): Here's What You Should Know

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Swapnil Malekar - Piper Sandler Sam Slutsky - LifeSci Capital Emily Bodnar - H.C. Wainwright Alex Thompson - Stifel Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Third Quarter 2022 Earnings Conference Call.

Ventyx Biosciences, Inc. (VTYX) Q3 2022 Earnings Call Transcript

We are on track to initiate Phase 2 trials of our allosteric TYK2 inhibitor VTX958 in psoriasis, Crohn's disease and psoriatic arthritis this quarter

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the third quarter ended September 30, 2022 after market close on November 3, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

After losing some value lately, a hammer chart pattern has been formed for Ventyx Biosciences, Inc. (VTYX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Ventyx Biosciences, Inc. (VTYX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Acumen Pharmaceuticals

Akero Therapeutics Inc

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Immuneering Corp

Novavax

Cassava Sciences Inc

Value Line

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

Bristol-Myers

Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu.

Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying Both

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Verona Pharma

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The biotech benefits from a much larger peer's recent FDA approval.

Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week

Source: metamorworks / Shutterstock Ventyx Biosciences (NASDAQ: VTYX ) stock is rocketing higher on Monday after Oppenheimer analyst Jeff Jones provided an update on the shares. That update has the Oppenheimer analyst increasing his price target for VTYX stock from $40 per share to $65 per share.

Why Is Ventyx Biosciences (VTYX) Stock Up 70% Today?

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Yasmeen Rahimi - Piper Sandler Michael Yee - Jefferies Josh Schimmer - Evercore ISI Tiago Fauth - Credit Suisse Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Operator Thank you for standing by and welcome to the Ventyx Biosciences' Second Quarter 2022 Earnings Conference Call. At this time all participants are in listen only mode.

Ventyx Biosciences, Inc. (VTYX) CEO Raju Mohan on Q2 2022 Results - Earnings Call Transcript

VTX958, our allosteric TYK2 inhibitor, demonstrated an excellent safety profile and class-leading target coverage in Phase 1 trial

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

VTX958 was well-tolerated across all SAD and MAD cohorts with an excellent safety profile

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

ENCINITAS, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need today announced that it will report topline results from the Phase 1 trial of its selective, allosteric TYK2 inhibitor VTX958 as well as financial results for the second quarter ended June 30, 2022, after market close on August 15, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT on August 15, 2022 to discuss the VTX958 Phase 1 results.

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

Excellent safety, tolerability and pharmacokinetic profile

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

ENCINITAS, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview during a fireside chat at the Jefferies Healthcare Conference being held June 8-10, 2022.

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Participants Yasmeen Rahimi – Piper Sandler Josh Schimmer – Evercore ISI Michael Yee – Jefferies Tiago Fauth – Credit Suisse Sam Slutsky – LifeSci Capital Jeff Jones – Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Ventyx Biosciences First Quarter 2022 Financial Results Conference Call.

Ventyx Biosciences' (VTYX) CEO Raju Mohan on Q1 2022 Results - Earnings Call Transcript

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.

News for Ventyx Biosciences Stock (VTYX)